Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Aug 29, 2018 • 9:00 AM EDT
Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference
Aug 9, 2018 • 8:08 AM EDT
Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash
Aug 6, 2018 • 4:01 PM EDT
Ligand Reports Second Quarter 2018 Financial Results
Sep 5, 2018 • 12:30pm EDT
St. Regis Hotel, New York, NY
See all events
Aug 6, 2018 • 4:30pm EDT
Jun 19, 2018 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
$VKTX announces positive top-line results from Phase 2 study of VK2809 in patients with Non-Alcoholic Fatty Liver D… https://t.co/YTXXaT8Ecl
Opthea presents Phase 1/2a data of OPT-302 in wet AMD at the Retina Society 2018 annual meeting https://t.co/81sXugliin
$MACK completes enrollment in randomized Phase 2 SHERLOC study of MM-121 (seribantumab) in Non-Small Cell Lung Canc… https://t.co/XyJU3fOyLt